Spots Global Cancer Trial Database for abvd
Every month we try and update this database with for abvd cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma | NCT01118026 | Lymphoma | ABVD BEACOPP radiation thera... | 18 Years - 60 Years | Alliance for Clinical Trials in Oncology | |
| Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | NCT02275598 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 8 Years - 70 Years | University of Modena and Reggio Emilia | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | NCT01251107 | Hodgkin Lymphom... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Doxorubicin Bleomycin Vinblastine Dacarbazine | 17 Years - 60 Years | Fondazione Michelangelo | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | NCT00816959 | Hodgkin's Lymph... | R-mabHDI and AB... ABVD | 16 Years - 65 Years | American Scitech International | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients | NCT00784537 | Hodgkin's Lymph... | ABVD ABVD and Radiot... | 18 Years - 70 Years | Fondazione Italiana Linfomi - ETS | |
| Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | NCT01578967 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | NCT02275598 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 8 Years - 70 Years | University of Modena and Reggio Emilia | |
| Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma | NCT00722865 | Hodgkin Lymphom... | Avastin | 18 Years - | Massachusetts General Hospital | |
| Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | NCT00797472 | Hodgkin's Disea... | R-mabHD ABVD | 18 Years - 65 Years | American Scitech International | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | NCT01578967 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes | NCT01304849 | Hodgkin's Lymph... | Escalated BEACO... | 12 Years - 65 Years | Cancer Institute WIA | |
| Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes | NCT01304849 | Hodgkin's Lymph... | Escalated BEACO... | 12 Years - 65 Years | Cancer Institute WIA | |
| Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | NCT00797472 | Hodgkin's Disea... | R-mabHD ABVD | 18 Years - 65 Years | American Scitech International | |
| OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | NCT03527628 | Classical Hodgk... Hodgkin Lymphom... Hodgkin Disease Hodgkin Lymphom... | Adriamycin Cyclophosphamid... Vinblastine Dacarbazine Brentuximab Ved... ABVD | 14 Years - 60 Years | King Abdullah International Medical Research Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
